主页 /
搜索结果：“ehop 016”

“ehop 016”的搜索结果

Quick View
ETC-1002

Catalog No. A15815
Quick View

添加到收藏
ACL 抑制剂 and AMPK 激活剂

ETC-1002是一种新颖的，一流的可以降低LDL-C的小分子；肝AMP激活的蛋白激酶（AMPK）的激活剂;对肝ATP-柠檬酸裂解酶也具有有效的抑制活性（IC50 = 29 uM）。了解更多

Bulk Inquiry Free Sample
Quick View
YM201636

Catalog No. A11064
Quick View

添加到收藏
PI3K 抑制剂

YM201636是PIKfyve的细胞渗透性和选择性抑制剂（IC50 = 33 nM）。了解更多

Product Citations (2)

Bulk Inquiry Free Sample
- Krishna Chintaluri, .et al. The PH domain from the Toxoplasma gondii PH-containing protein-1 (TgPH1) serves as an ectopic reporter of phosphatidylinositol 3-phosphate in mammalian cells, PLoS One, 2018, 13(6): e0198454 PMID: 29870544
- Dayam RM, .et al. The Lipid Kinase PIKfyve Coordinates the Neutrophil Immune Response through the Activation of the Rac GTPase, J Immunol, 2017, Sep 15;199(6):2096-2105 PMID: 28779020
Quick View
BKM120 (NVP-BKM120, Buparlisib)

Catalog No. A11016
Quick View

添加到收藏
PI3K 抑制剂?

BKM120 (NVP-BKM120,Buparlisib)是生物可利用的口服泛I类磷脂酰肌醇3激酶（PI3K）激酶抑制剂，在无细胞试验中作用于p110α/β/δ/γ的。对VPS34，mTOR，DNAPK的作用效果下降，而对 PI4Kβ几乎没有活性。了解更多

Product Citations (11)

Bulk Inquiry Free Sample
- Giri R. Gnawali, .et al. Synthesis of 2-oxoquinoline derivatives as dual pim and mTORC protein kinase inhibitors, Medicinal Chemistry Research, 2022, 31: 1154-1175
- Yusuke Murase, .et al. Antitumor activity of the dual PI3K/mTOR inhibitor gedatolisib and the involvement of ABCB1 in gedatolisib resistance in canine tumor cells, Oncol Rep, 2022, Apr;47(4):61 PMID: 35088890
- Jeremiah J Bearss, .et al. EDC3 phosphorylation regulates growth and invasion through controlling P-body formation and dynamics, EMBO Rep, 2021, Apr 7;22(4):e50835 PMID: 33586867
- Takaaki Fujimura, .et al. Enhanced antitumor effect of alectinib in combination with cyclin-dependent kinase 4/6 inhibitor against RET-fusion-positive non-small cell lung cancer cells, Cancer Biol Ther, 2020, Sep 1;21(9):863-870 PMID: 32835580
- Nachi Namatame, .et al. Antitumor profile of the PI3K inhibitor ZSTK474 in human sarcoma cell lines, Oncotarget, 2018, Oct 12; 9(80): 35141-35161 PMID: 30416685
- Jin H. Song, .et al. Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase, Mol Cancer Ther, 2018, Dec;17(12):2710-2721 PMID: 30190422
- Saijo A, .et al. Bone marrow-derived fibrocytes promote stem cell-like properties of lung cancer cells, Cancer Lett, 2018, May 1;421:17-27 PMID: 29448000
- Hirosumi Tamura, .et al. Evaluation of anticancer agents using patient-derived tumor organoids characteristically similar to source tissues, Oncol Rep, 2018, Aug; 40(2): 635-646 PMID: 29917168
- Pridham KJ, .et al. PIK3CB/p110β is a selective survival factor for glioblastoma, Neuro Oncol, 2018, Mar 27;20(4):494-505 PMID: 29016844
- Charles-André Philip, .et al. Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors, BMC Cancer, 2017, 17: 638 PMID: 28886696
- Rogers HA, .et al. PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival., Clin Cancer Res., 2013, Dec 1;19(23):6450-60 PMID: 24077346